XenaCare Holdings Announces Upcoming Cobroxin Advertising In The NCAA March Madness Tournament Program

XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, announced today that it has signed an agreement with Professional Sports Publications (PSP) to advertise Cobroxin in the upcoming National Collegiate Athletic Association (NCAA) March Madness Tournament Program and Final Four Game Program. PSP is the largest publisher of gameday programs, magazines and yearbooks in the United States. In addition to publishing the NCAA Official Tournament Program, PSP works with over 100 professional sports franchises throughout the four major sports, as well as numerous universities coast to coast.

“The NCAA March Madness Tournament is one of the most popular sports tournaments in North America with an average of 24.6 million households watching at least a portion of the games,” explained Frank Rizzo, President and CEO of XenaCare Holdings. “This tournament represents an important demographic for Cobroxin. We look forward to working closely with Professional Sports Publications to continue building awareness and exposure for the Cobroxin brand among NCAA sports enthusiasts,” he added.

Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. The drug is currently available as an oral spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additional benefits to Cobroxin include:

• All Natural
• Non-Addictive
• Non-Narcotic
• Non-Opiate
• Long Lasting

XenaCare Holdings was granted a license by Nutra Pharma Corporation (OTCBB: NPHC) to market and distribute Cobroxin within the United States.

About XenaCare Holdings

XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin, for the treatment of moderate to severe (Stage 2) chronic pain, the Company’s clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. In addition, the company offers formulations for the lifestyle performance market, which consists of a sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet as well as pharmacies. The company was founded in 2001 and is based in Delray Beach, Florida.